Premium
RANTES/CCL5 polymorphisms as a risk factor for recurrent acute rejection
Author(s) -
Krüger Bernd,
Böger Carsten A.,
Obed Aiman,
Farkas Stefan,
Hoffmann Ute,
Banas Bernhard,
Fischereder Michael,
Krämer Bernhard K.
Publication year - 2007
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2006.00654.x
Subject(s) - medicine , chemokine , ccl5 , pathogenesis , immunology , transplantation , kidney transplantation , kidney disease , genotype , gene , inflammation , t cell , genetics , immune system , biology , il 2 receptor
Background: The chemokine system plays an important role in the pathogenesis of acute rejection or atherosclerosis. Three polymorphisms in the promoter region of the chemokine RANTES (−403G/A, −28G/C, In1.1T/C) are associated with a different expression of this chemokine as well as the occurrence of cardiovascular disease. Therefore, we investigated the impact of these three polymorphisms on the outcome after renal transplantation. Methods: In 261 patients receiving their first kidney transplant, we genotyped the RANTES promoter polymorphisms (−403G/A, −28G/C, In1.1T/C) by real‐time PCR. Results: For the RANTES −403G/A and for the intronic polymorphism In1.1T/C, we found a significantly higher rate of recurrent acute rejection episodes (−403G/A: 11.1 vs. 31.0%, In1.1T/C: 11.8 vs. 33.0%). For the overall rate of acute rejection, we observed no significant differences according to the RANTES promoter polymorphisms. The other tested variables (DGF, graft survival, renal function) were not associated with one of the three polymorphisms. Conclusion: Our data indicate a relevant role of RANTES in kidney transplantation, particularly for the occurrence of recurrent acute rejection. To clarify the role of the analysed polymorphisms for long‐term survival, especially for the occurrence of cardiovascular events, larger studies in the future are needed.